PPH
VanEck Pharmaceutical ETF · NAS
- Category Equity
- Expense Ratio 0.36%
- Listing Date Feb 01, 2000
- Volume 24,910.0
- Market Cap (AUM) $571.89M
Performance
+1.04%
1W
+6.03%
1M
+1.8%
3M
+18.61%
6M
+11.56%
YTD
+17.73%
1Y
Top Holdings
-
Name
Symbol%Assets
- Eli Lilly and CompanyLLY11.89%
- Novo Nordisk A/S Sponsored ADR Class BNVO9.88%
- Johnson & JohnsonJNJ6.43%
- Merck & Co., Inc.MRK6.21%
- Astrazeneca PLC Sponsored ADRAZN5.83%
- AbbVie, Inc.ABBV5.45%
- Novartis AG Sponsored ADRNVS5.02%
- GSK plc Sponsored ADRGSK4.77%
- Pfizer Inc.PFE4.72%
- McKesson CorporationMCK4.67%
Technical Analysis of PPH 2024-05-10
Overview:
In analyzing the technical indicators for PPH over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and recommendations for potential ...
Recent News & Updates
- 2018-09-28 06:03
- 2018-07-03 03:19
July Could Be a Volatile Month for Pharma ETFs(Yahoo Finance)
- 2018-06-29 06:15
- 2018-06-03 22:38
Biogen Inc Stock Got an Upgrade, but Should You Listen?(Yahoo Finance)
- 2018-04-23 18:41
- 2018-03-29 05:58
- 2018-01-24 20:00
Tasigna Could Boost Novartiss Revenue Growth in 2018(Marketrealist)
- 2018-01-24 18:31
- 2018-01-21 21:00
- 2018-01-21 18:34
Johnson & Johnsons Consumer Segment: 4Q17 Estimates(Marketrealist)
- 2018-01-14 21:31
- 2018-01-09 23:03
Mylans Valuation in January 2018(Marketrealist)
- 2018-01-08 21:31
- 2018-01-07 18:33
- 2018-01-04 21:35
- 2017-12-26 05:15
- 2017-11-22 04:30
- 2017-11-14 01:35
Understanding Sanofis Revenues by Segment in 3Q17(Marketrealist)
- 2017-10-16 00:33
- 2017-10-02 00:35
- 2017-09-29 05:25
- 2017-09-19 22:36
- 2017-09-18 22:38
An Update on Novartiss Sandostatin, Afinitor, and Exjade(Marketrealist)
- 2017-09-13 19:39
TEVA Depends on This for Revenue Growth(Marketrealist)
- 2017-09-10 22:36
- 2017-09-10 19:36
- 2017-09-05 21:06
Performance of AstraZenecas Other Products in 2Q17(Marketrealist)
- 2017-09-04 19:37
Performance of AstraZenecas Growth Platforms in 2Q17(Marketrealist)
- 2017-09-03 21:06
Performance of Eli Lillys Neuroscience Products in 2Q17(Marketrealist)
- 2017-08-31 00:34
Changes in GlaxoSmithKlines Valuation after 2Q17(Marketrealist)
- 2017-08-30 19:38
How Novartiss Sandoz Performed in 2Q17(Marketrealist)
- 2017-08-29 19:36
Johnson & Johnsons Medical Devices Segment in 2Q17(Marketrealist)
- 2017-08-22 23:53
JAZZ Is Focused on Increasing Market Adoption of Defitelio(Marketrealist)
- 2017-08-22 21:53
- 2017-08-21 04:05
Inside Jazzs Net Profit Margin Expectations for 2017(Marketrealist)
- 2017-08-16 19:37
Sanofis Revenue Growth in 2Q17(Marketrealist)
- 2017-08-14 21:06
Pfizers Important Product Developments in 2Q17(Marketrealist)
- 2017-08-13 22:25
- 2017-08-06 21:53
- 2017-07-31 23:21